Jun 25, 2019
Eisai Presents Data To Assess Seizure Freedom With FYCOMPA® Monotherapy In Newly Diagnosed Or Untreated Patients With Partial Onset Seizures
Jun 13, 2019
Eisai To Present FYCOMPA® Seizure FREEDOM Data In New Onset Patients And Pediatric Data At The 33rd International Epilepsy Congress
Jun 11, 2019
Extensive Analyses of Phase 3 Data for Investigational Lemborexant Assess Efficacy and Safety Profile for the Potential Treatment of Insomnia in Adults
May 29, 2019
Adriana Herrera Appointed Senior Vice President, Americas Commercial Oncology at Eisai Inc.
May 28, 2019
Eisai to Present Eight Lemborexant Posters at SLEEP 2019 Meeting, Including New Pooled Analyses From Phase 3 Studies and New Phase 1 Data
May 16, 2019
Eisai Announces Data Presentations on Oncology Pipeline, including LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Investigational Combination Therapy at ASCO 2019
May 10, 2019
Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease
May 09, 2019
Lower Hospitalization Rates In Epilepsy Patients Treated With Adjunctive FYCOMPA® (perampanel) CIII
Apr 30, 2019
Eisai and Purdue Pharma Announce Buy Out of Purdue's Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant
Apr 01, 2019
ADVANZ PHARMA Corp. Acquires International Rights to Two Medicines
Mar 29, 2019
Data Safety Monitoring Board Recommends Continuation Of Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Mar 22, 2019
Initiation Of Phase III Clinical Trial Of BAN2401 In Early Alzheimer's Disease
Mar 13, 2019
TRIA to Design New Dementia Discovery Center for Eisai Inc.
Mar 11, 2019
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
Mar 06, 2019
Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference
Feb 25, 2019
FDA Accepts Eisai's Supplemental New Drug Application (sNDA) to Update the Labeling for Anti-Obesity Agent BELVIQ® (lorcaserin HCl)
Feb 19, 2019
Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.
Feb 11, 2019
METAvivor and Presenting Sponsor Eisai Inc. Join Forces with AnaOno Intimates to Bring to Life the #ThisIsMBC Elements Campaign through Fashion
Jan 15, 2019
New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
Jan 07, 2019
Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis